(1R,2r)-甲基2-氨基环戊烷羧酸 | 170421-23-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1R,2r)-甲基2-氨基环戊烷羧酸
• 中文别名: (1R,2R)-2-氨基环戊烷-1-羧酸甲酯；(1R,2R)-甲基2-氨基环戊烷羧酸
• 英文名称: (1R,2R)-2-aminocyclopentanecarboxylic acid methyl ester
• 英文别名: Methyl (1R,2R)-2-aminocyclopentane-1-carboxylate
• CAS: 170421-23-5
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: RGXCCQQWSIEIEF-PHDIDXHHSA-N

物化性质

• 沸点：
  193.0±33.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2′-双(溴甲基)-1,1′-联苯 、 (1R,2r)-甲基2-氨基环戊烷羧酸 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  α-和β-氨基酯的6,7-二氢-5 H -dibenz [ c，e ]氮杂环庚烷衍生物的中心-轴向手性转移和诱导的圆二色性

  摘要：

  DAZ-的Xaa * -OMe氨基酯与衍生物的Xaa *  = d / L丙氨酸，d / L-Val取代，1-亮氨酸，L-异亮氨酸，L-丝氨酸，L-β 3 -HAla，1-β 3 -HVal ，1-β 3 -HLeu，（1小号，2小号）/（1 - [R，2 - [R）-ACHC（2-氨基环己烷羧酸）和（1小号，2小号）/（1 - [R，2 - [R）-ACPC（ （2-氨基环戊烷羧酸），被N-保护为6,7-二氢-5 H -dibenz [ c，e已合成] azazines（DAZ）并通过联苯发色团的诱导圆二色性评估α-和β-氨基酯的绝对构型，并对其进行了评估。

  DOI：

  10.1016/j.tetlet.2008.03.087

文献信息

• Dolastatin 15 derivatives
  申请人：BASF Aktiengesellschaft

  公开号：US20010018422A1

  公开（公告）日：2001-08-30

  Compounds of the present invention include cell growth inhibitors which are peptides of Formula I A-B-D-E-F-G (I) and acid salts thereof, wherein A, D, and E are &agr;-amino acid residues, B is an &agr;-amino acid residue or an &agr;-hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sultoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

  本发明的化合物包括细胞生长抑制剂，其为公式IA-B-D-E-F-G（I）及其酸盐的肽，其中A、D和E为α-氨基酸残基，B为α-氨基酸残基或α-羟基酸残基，F为氨基苯甲酸残基或氨基环烷基羧酸残基，G为单价基团，例如氢原子，氨基团，烷基，烷基乙醚，烷基硫醚，烷基醛，烷基酰胺，β-羟基氨基团，肼基，烷氧基，硫代烷氧基，氨氧基，肟基，烷基芳基基团，烷基酯，烷基磺酸酯或烷基磺酸酰。本发明的另一个方面包括含有公式I化合物和药学上可接受的载体的制药组合物。本发明的另一个实施例是一种治疗哺乳动物，例如人类癌症的方法，包括向哺乳动物内部注射药学上可接受的公式I化合物的有效量。
• DOLASTATIN 15 DERIVATIVES
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1093460A1

  公开（公告）日：2001-04-25
• PIPERIDINES AS MENIN INHIBITORS
  申请人：The Regents of The University of Michigan

  公开号：EP3452461B1

  公开（公告）日：2021-09-08
• US5985837A
  申请人：——

  公开号：US5985837A

  公开（公告）日：1999-11-16
• [EN] DOLASTATIN 15 DERIVATIVES<br/>[FR] DERIVES DE DOLASTATINE 15
  申请人：BASF AG

  公开号：WO2000002906A1

  公开（公告）日：2000-01-20

  Compounds of the present invention include cell growth inhibitors which are peptides of Formula (I): A - B - D - E - F - G and acid salts thereof, wherein A, D and E are α-amino acid residues, B is an α-amino acid residue or an α-hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula (I) in a pharmaceutically acceptable composition.